| 1 |
34909649 | Reversal of TGF-β-induced epithelial-mesenchymal transition in hepatocellular carcinoma by sorafenib, a VEGFR-2 and Raf kinase inhibitor. | 2021 |
1 |
| 2 |
32750425 | Valproic acid overcomes sorafenib resistance by reducing the migration of Jagged2-mediated Notch1 signaling pathway in hepatocellular carcinoma cells. | 2020 Sep |
1 |
| 3 |
29514844 | COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment. | 2018 Jul 1 |
2 |
| 4 |
29258450 | Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study. | 2017 Dec 19 |
1 |
| 5 |
26046304 | Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib. | 2015 Aug 28 |
1 |
| 6 |
24486412 | Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells. | 2014 May |
4 |
| 7 |
16425993 | Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. | 2005 Dec |
1 |